Mitchell L. Shiffman

TL;DR: In patients with chronic hepatitis C and cirrhosis or bridging fibrosis, 180 microg of peginterferon alfa-2a administered once weekly is significantly more effective than 3 million units of standard interferonAlfa- 2a administered three times weekly.

TL;DR: Obeticholic acid administered with ursodiol or as monotherapy for 12 months in patients with primary biliary cholangitis resulted in decreases from baseline in alkaline phosphatase and total bilirubin levels that differed significantly from the changes observed with placebo.

TL;DR: Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment withSofosBuvir-ribavirin.

TL;DR: PegIntron alfa‐2b maintained the clinical efficacy of interferon alfa'2b while preserving its safety profile and increased virologic response rates after treatment and after follow‐up, as compared with interferons alfa'; however, the higher rate of virolic response during treatment with 1.5 μg/kg peginterferonAlfa‐ 2b in patients infected with genotype 1 and high viral levels warrants further evaluation.

TL;DR: Early, sustained suppression of HCV replication portends an SVR, and cessation of treatment may be contemplated in patients without a > or = 2 log10 reduction in HCV RNA after 12 weeks.